Beizray
Payments companies reported to CMS as associated with Beizray. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Beizray, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Beizray
These are the largest totals companies reported as associated with Beizray. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Gary Kay | Elk Grove Village, IL | Hematology & Oncology | $196.86 |
| Dana Pisillo | Sarasota, FL | Nurse Practitioner | $69.30 |
| Galina Vugman | Sarasota, FL | Medical Oncology | $69.30 |
| Eric Fox | Bryn Mawr, PA | Hematology & Oncology | $69.12 |
| Marie Scutti | Bryn Mawr, PA | Nurse Practitioner | $69.12 |
| Kristina Bonesteel | Bryn Mawr, PA | Nurse Practitioner | $69.12 |
| John Devlin | Bryn Mawr, PA | Hematology & Oncology | $69.12 |
| Chloe Perate | Bryn Mawr, PA | Physician Assistant | $69.09 |
| Hamed Khosravi | Woodbridge, VA | Hematology & Oncology | $50.70 |
| Navid Mokhtari Amirmajdi | Towson, MD | Hematology & Oncology | $50.70 |
Prescribed Beizray?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.